Published in Lab Business Week, July 16th, 2006
According to recent research published in the British Journal of Cancer, "In advanced colorectal cancer previously treated with oxaliplatin, efficacy of irinotecan-based chemotherapy is poor and the best regimen is not defined. We designed FOLFIRI-3 and conducted a phase II study to establish its efficacy and safety in advanced colorectal cancer patients previously treated with FOLFOX."
"FOLFIRI-3 consisted of irinotecan 100 mg/m2 as a 60-min infusion on day 1, running...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week